FDA hands Neurocrine approvable letter

Neurocrine investors won't be sleeping well tonight. The company's stock plummeted 45 percent after the FDA said that it would need additional data on its sleep therapy indiplon before it can be approved. Shares sank to $4.60, well below its 52-week low of $9. Neurocrine's indiplon has been in regulatory limbo since the middle part of last year, when its 15 mg dose ran afoul of the FDA. It resubmitted its application for 5 mg and 10 mg doses six months ago.

"While we are disappointed in the FDA action, we will accept the FDA's offer to discuss the applications via a meeting or telephone conference in order to clarify and determine the next steps required," said Neurocrine President and Chief Executive Gary A. Lyons.

- see this release on the FDA's decision
- check out the AP's report on the fallout

Related Articles:
Neurocrine shares sink on news of indiplon delay. Report
FDA wants more data on Neurocrine's indiplon. Report
Deep cuts reported at Neurocrine, Valentis. Report
Struggling to save cash, Neurocrine axes sales force. Report
The Biotech Haunted House. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.